Period of immunity following complete vaccination towards SARS-CoV-2: a scientific assessment | Archives of Public Well being


  • Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Research of COVID-19 Vaccine Sort and Antagonistic Results Following Vaccination. JAMA Netw Open. 2021;4(12):e2140364.

    Article 

    Google Pupil 

  • Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Leap forward Infections in Vaccinated Well being Care Employees. N Engl J Med. 2021;385(16):1474–84.

    CAS 
    Article 

    Google Pupil 

  • Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, et al. SARS-CoV-2 Variants and Vaccines. N Engl J Med. 2021;385(2):179–86.

    CAS 
    Article 

    Google Pupil 

  • Jecker NS, Wightman AG, Diekema DS. Vaccine ethics: a moral framework for international distribution of COVID-19 vaccines. J Med Ethics. 2021;47(5):308–17.

    Google Pupil 

  • Pivetti M, Di Battista S, Paleari FG, Hakoköngäs E. Conspiracy ideals and attitudes towards COVID-19 vaccinations. 2021.

  • Islam MS, Kamal AM, Kabir A, Southern DL, Khan SH, Hasan SMM, et al. COVID-19 vaccine rumors and conspiracy theories: The desire for cognitive inoculation towards incorrect information to reinforce vaccine adherence. PLoS One. 2021;16(5):e0251605.

    CAS 
    Article 

    Google Pupil 

  • Tenforde MW, Self WH, Adams Okay, Gaglani M, Ginde AA, McNeal T, et al. Affiliation Between mRNA Vaccination and COVID-19 Hospitalization and Illness Severity. JAMA. 2021;326(20):2043–54.

    CAS 
    Article 

    Google Pupil 

  • Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, et al. COVID-19 health facility admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2· 57 million other folks in Scotland (EAVE II): a potential cohort find out about. Lancet Respir Med. 2021;9(12):1439–49.

    CAS 
    Article 

    Google Pupil 

  • Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 leap forward infections in vaccinated folks: size, reasons and have an effect on. Nat Rev Immunol. 2022;22(1):57–65.

    CAS 
    Article 

    Google Pupil 

  • Anand P, Stahel VP. Assessment the protection of Covid-19 mRNA vaccines: a assessment. Affected person Saf Surg. 2021;15(1):20.

    Article 

    Google Pupil 

  • Xing Okay, Tu XY, Liu M, Liang ZW, Chen JN, Li JJ, et al. Efficacy and protection of COVID-19 vaccines: a scientific assessment. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(3):221–8.

    PubMed 

    Google Pupil 

  • Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and Protection of COVID-19 Vaccines: A Systematic Assessment and Meta-Research of Randomized Scientific Trials. Vaccines (Basel). 2021;9(5):467.

    CAS 
    Article 

    Google Pupil 

  • Web page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. observation: an up to date guiding principle for reporting systematic evaluations. BMJ. 2020;2021:372.

    Google Pupil 

  • Australian Technical Advisory Crew on Immunisation. ATAGI suggestion at the definition of totally vaccinated Australia: ATAGI; 2021. To be had from: https://www.fitness.gov.au/assets/publications/atagi-advice-on-the-definition-of-fully-vaccinated.

  • Tsatsakis A, Vakonaki E, Tzatzarakis M, Flamourakis M, Nikolouzakis TK, Poulas Okay, et al. Immune reaction (IgG) following complete inoculation with BNT162b2 COVID-19 mRNA amongst healthcare pros. Int J Mol Med. 2021;48(5):1–10.

    Article 

    Google Pupil 

  • Facilities for Illness Keep an eye on and Prevention. Word list United States: U.S. Division of Well being & Human Services and products; 2020. To be had from: https://www.cdc.gov/vaccines/phrases/word list.html.

  • Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al. Spike-antibody waning after 2nd dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385–7.

    CAS 
    Article 

    Google Pupil 

  • Facilities for Illness Keep an eye on and Prevention. Vaccines & Immunizations United States: U.S. Division of Well being & Human Services and products; 2021. To be had from: https://www.cdc.gov/vaccines/vac-gen/immunity-types.htm.

  • Sterne JAC, Savovic J, Web page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised software for assessing chance of bias in randomised trials. BMJ. 2019;366:l4898.

    Article 

    Google Pupil 

  • Shu YJ, He JF, Pei RJ, He P, Huang ZH, Chen SM, et al. Immunogenicity and protection of a recombinant fusion protein vaccine (V-01) towards coronavirus illness 2019 in wholesome adults: a randomized, double-blind, placebo-controlled, segment II trial. Chin Med J (Engl). 2021;134(16):1967–76.

    Article 

    Google Pupil 

  • Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral Reaction to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021;385(24):e84.

    CAS 
    Article 

    Google Pupil 

  • Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Van Eechhoudt S, et al. Antibody titers decline 3-month post-vaccination with BNT612b2. 2021.

  • Taylor SC, Hurst B, Martiszus I, Hausman MS, Sarwat S, Schapiro JM, et al. Semi-quantitative, top throughput research of SARS-CoV-2 neutralizing antibodies: Measuring the extent and period of immune reaction antibodies publish an infection/vaccination. Vaccine. 2021;39(39):5688–98.

    CAS 
    Article 

    Google Pupil 

  • Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, et al. The neutralizing antibody reaction publish COVID-19 vaccination in sufferers with myeloma is extremely depending on the kind of anti-myeloma remedy. Blood Most cancers J. 2021;11(8):1–9.

    Article 

    Google Pupil 

  • Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and immunogenicity after a overdue 2nd dose or a 3rd dose of ChAdOx1 nCoV-19 in the United Kingdom: a substudy of 2 randomised managed trials (COV001 and COV002). Lancet. 2021;398(10304):981–90.

    CAS 
    Article 

    Google Pupil 

  • Collier DA, Ferreira I, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune reaction heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417–22.

    CAS 
    Article 

    Google Pupil 

  • Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Protection and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: period in-between effects from a double-blind, randomised, multicentre, segment 2 trial, and 3-month follow-up of a double-blind, randomised segment 1 trial. Lancet Infect Dis. 2021;21(7):950–61.

    CAS 
    Article 

    Google Pupil 

  • Glöckner S, Hornung F, Baier M, Weis S, Pletz MW, Deinhardt-Emmer S, et al. Tough Neutralizing Antibody Ranges Detected after Both SARS-CoV-2 Vaccination or One Yr after An infection. Viruses. 2021;13(10):2003.

    Article 

    Google Pupil 

  • Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021;385(24):e85.

    CAS 
    Article 

    Google Pupil 

  • Guerrera G, Picozza M, D’Orso S, Placido R, Pirronello M, Verdiani A, et al. BNT162b2 vaccination induces sturdy SARS-CoV-2-specific T cells with a stem mobile reminiscence phenotype. Sci Immunol. 2021;6(66):eabl5344.

  • Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al. A initial document of a randomized managed segment 2 trial of the protection and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39(20):2791–9.

    CAS 
    Article 

    Google Pupil 

  • Israel A, Merzon E, Schäffer AA, Shenhar Y, Inexperienced I, Golan-Cohen A, et al. Elapsed time since BNT162b2 vaccine and chance of SARS-CoV-2 an infection in a big cohort. MedRxiv. 2021.

  • Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Ahmad YA, Saffuri A, et al. COVID-19 vaccine–Long run immune decline and leap forward infections. Vaccine. 2021;39(48):6984–9.

    CAS 
    Article 

    Google Pupil 

  • Frater J, Ewer KJ, Ogbe A, Tempo M, Adele S, Adland E, et al. Protection and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine towards SARS-CoV-2 in HIV an infection: a single-arm substudy of a segment 2/3 medical trial. Lancet HIV. 2021;8(8):e474–85.

    Article 

    Google Pupil 

  • Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Hyperlink-Gelles R, Jernigan JA, Budnitz D, Bell J, Benin A, Shang N, Edwards JR, Verani JR, Schrag SJ. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Combating SARS-CoV-2 An infection Amongst Nursing House Citizens Prior to and All over Common Movement of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Nationwide Healthcare Protection Community, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-6. https://doi.org/10.15585/mmwr.mm7034e3.

  • Richmond PC, Hatchuel L, Pacciarini F, Hu B, Smolenov I, Li P, et al. Endurance of the Immune Responses and Pass-Neutralizing Process With Variants of Worry Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Illness 2019 Vaccine. J Infect Dis. 2021;224(10):1699–706.

    CAS 

    Google Pupil 

  • Racine-Brzostek SE, Yee JK, Sukhu A, Qiu Y, Rand S, Barone PD, et al. Fast, powerful, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 folks. JCI Perception. 2021;6(20):e151477.

    Article 

    Google Pupil 

  • Naaber P, Tserel L, Kangro Okay, Sepp E, Jurjenson V, Adamson A, et al. Dynamics of antibody reaction to BNT162b2 vaccine after six months: a longitudinal potential find out about. Lancet Reg Well being Eur. 2021;10:100208.

    Article 

    Google Pupil 

  • Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine as much as 6 months in a big built-in fitness device in the US: a retrospective cohort find out about. Lancet. 2021;398(10309):1407–16.

    CAS 
    Article 

    Google Pupil 

  • Tober-Lau P, Schwarz T, Vanshylla Okay, Hillus D, Gruell H, Crew ECS, et al. Lengthy-term immunogenicity of BNT162b2 vaccination in older other folks and more youthful health-care staff. Lancet Respir Med. 2021;9(11):e104–5.

  • Achiron A, Mandel M, Dreyer-Alster S, Harari G, Gurevich M. Humoral SARS-COV-2 IgG decay inside 6 months in COVID-19 wholesome vaccinees: The desire for a booster vaccine dose? Eur J Intern Med. 2021;94:105–7.

    CAS 
    Article 

    Google Pupil 

  • Aldridge RW, Yavlinsky A, Nguyen V, Eyre MT, Shrotri M, Navaratnam AMD, et al. Waning of SARS-CoV-2 antibodies focused on the Spike protein in folks publish 2nd dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and chance of leap forward infections: research of the Virus Watch group cohort. medRxiv. 2021.

  • Angel-Korman A, Peres E, Bryk G, Lustig Y, Indenbaum V, Amit S, et al. Decreased and waning immunity to COVID-19 vaccination amongst hemodialysis sufferers in Israel: the case for a 3rd vaccine dose. Clin Kidney J. 2021.

  • Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 Vaccine Coverage towards SARS-CoV-2 An infection in Qatar. N Engl J Med. 2021;385(24):e83.

    CAS 
    Article 

    Google Pupil 

  • Anderson EJ, Rouphael NG, Widge AT, Jackson LA, RobertsMakhene PC, et al. Protection and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383(25):2427–38.

    CAS 
    Article 

    Google Pupil 

  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Protection and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.

    CAS 
    Article 

    Google Pupil 

  • Baden LR, El Sahly HM, Essink B, Kotloff Okay, Frey S, Novak R, et al. Efficacy and Protection of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16.

    CAS 
    Article 

    Google Pupil 


  • Verepass helps sort through the science of COVID-19, process it, and offer an easy pathway to understanding your COVID-19 health, which will get you back to doing what you enjoy.